EC nod for Roche's first-in-class bispecific antibody Lunsumio for follicular lymphoma

8 June 2022
roche_basel_large-1

The European Commission has granted conditional marketing authorization for the CD20xCD3 T-cell engaging bispecific antibody Lunsumio (mosunetuzumab), developed by Swiss pharma giant Roche (ROG: SIX).

Lunsumio is indication for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least two prior systemic therapies. Lunsumio is an off-the-shelf therapy that is readily available, so people do not have to wait to start treatment. This follows a positive recommendation from the European Medicines Agency’s human medicines committee (CHMP) in April.

Mizuho Securities analyst Salim Syed has previously forecast peak sales of more than $1 billion for mosunetuzumab.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology